i

Significant reduction in MBL

Qlaira® is the first oral therapy approved for the treatment of HMB with added contraceptive benefit1

  • Oral, non-invasive, reversible, and fertility-conserving treatment
How much do you think Qlaira® reduces menstrual blood loss (MBL)?

- 24%

- 48%

x

Abstract1

OBJECTIVE:

To evaluate the efficacy of oestradiol valerate/dienogest (E2V/DNG) for the treatment of heavy and/or prolonged menstrual bleeding without organic pathology based on the analysis of data from two identically designed double-blind, randomised studies.

METHODS:

Women aged 18 years with heavy and/or prolonged menstrual bleeding were randomised to E2V/DNG (n = 269) or placebo (n = 152) for 196 days. Objective changes in menstrual blood loss (MBL) volume were assessed using the alkaline haematin method.

RESULTS:

After six months of treatment, median MBL decreased by 88% with E2V/DNG compared with 24% with placebo. The greatest reduction was achieved at the first withdrawal bleed after treatment initiation and it was sustained with no loss of effect throughout treatment.

CONCLUSION:

E2V/DNG was more effective than placebo in reducing MBL in women with heavy and/or prolonged menstrual bleeding without organic pathology. The reduction was largely achieved as early as the first withdrawal bleed, with further gradual improvement throughout treatment.